← Leaderboards
Deepa Sampath
Ohio State University
$2,215,864
Attributed
$5,208,740
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2018–24$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,208,740 · 2
By mechanism
R01$5,208,740 · 2
Top collaborators
- Vinay K Puduvalli6 shared
- Rosa Lapalombella5 shared
- Alice Scott Mims5 shared
Most similar at Ohio State University
Same institution · by research overlap
- Rosa Lapalombella$5,349,017
- Danilo Perrotti$4,143,140
- Alice Scott Mims$1,588,136
- Shujun Liu$5,854,035
- Jennifer A. Woyach$6,733,332
Others in their field
Other Emerging Leaders on “Toxic Effect”
- Matthew Johnson · Duke University$56,071,536
- John Damon Chodera · Sloan-Kettering Inst Can Research$25,853,758
- Kristin Aillon · Midwest Research Institute$24,228,962
- Bronwen Shaw · Medical College Of Wisconsin$19,182,557
- Xinhua Li · Nano Terra, Inc.$17,491,533
- Thomas Denny · Duke University$16,626,143
Research focus
Toxic EffectSignal TransductionResponseNormal CellProteinsPre-ClinicalGenerationsDna RepairNeoplastic CellMouse ModelNovel TherapeuticsPharmaceutical PreparationsPharmacodynamicsPhase I Clinical TrialsCellsCell SurvivalComplexCytotoxicAffectIn VitroIn VivoMediatingCell LineTumor
Grant awards (11)
A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma$541,645
R01 · FY2024 · CA
A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma$568,351
R01 · FY2023 · CA
A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma$570,459
R01 · FY2022 · CA
Targeting NAMPT in Acute Myeloid Leukemia$461,498
R01 · FY2022 · CA
Targeting NAMPT in Acute Myeloid Leukemia$470,916
R01 · FY2021 · CA
A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma$560,714
R01 · FY2020 · CA
Targeting NAMPT in Acute Myeloid Leukemia$470,916
R01 · FY2020 · CA
Characterization of Onalespib, A novel long acting Hsp90 inhibitor, as a chemo and radiosensitizer in Adults with Newly Diagnosed Glioblastoma$33,147
R01 · FY2020 · CA
Characterization of Onalespib, A novel long acting Hsp90 inhibitor, as a chemo and radiosensitizer in Adults with Newly Diagnosed Glioblastoma$603,390
R01 · FY2019 · CA
Targeting NAMPT in Acute Myeloid Leukemia$456,788
R01 · FY2019 · CA
Targeting NAMPT in Acute Myeloid Leukemia$470,916
R01 · FY2018 · CA